Compass Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The COMPANION-002 trial in advanced biliary tract cancer showed that tovecimig plus paclitaxel significantly improved progression-free survival and overall response rate compared to paclitaxel alone, with a manageable safety profile. Crossover patients experienced notably prolonged survival, supporting plans for FDA submission and potential accelerated approval.
-
Four clinical-stage antibody programs are advancing, with tovecimig showing strong efficacy in biliary tract cancer and poised for key survival readouts. Commercialization plans target a >$1B U.S. market, with expansion into other indications and strategic partnerships under consideration.
Fiscal Year 2025
-
Multiple oncology assets are advancing, with Tevecimig showing strong efficacy in BTC and a pivotal PFS/OS readout expected in Q1 2026. PD-1, PD-L1 bispecifics demonstrate unique mechanisms and early responses in refractory patients, while commercial and prescriber readiness is ramping up for a potential 2027 launch.
-
Lead bispecific antibody Tovecimig demonstrated strong efficacy in advanced biliary tract cancer, with pivotal PFS/OS data expected by end of Q1 and a BLA filing planned for the second half of the year. Pipeline programs 8371 and 10726 are advancing, with global commercialization strategies under consideration.
-
Multiple antibody-based oncology drugs are advancing, with a lead bispecific showing significant efficacy in biliary tract cancer and key survival data expected in late Q1 2026. Early results from other pipeline assets are promising, and commercial opportunities are substantial.
-
COMPANION-002 trial of Tovecimig in second-line BTC shows fewer deaths than expected, suggesting a strong treatment effect, with top-line data due in late Q1 2026. Pipeline assets 8371 and CTX-10726 show promising early results, and the company is well-funded to advance multiple programs.
-
Four antibody-based oncology drugs will be in the clinic by early next year, with key data readouts expected in 2026. The lead program, Tuvesimig, showed a significant response rate improvement in BTC, with PFS and OS data due in late Q1. Additional pipeline programs are advancing, with robust early efficacy and safety signals.
-
Significant clinical progress was reported for Tavecimab in biliary tract cancer, with updated survival data and expanded studies planned. Novel bispecific antibodies H371 and 10726 showed promising early results, and strong manufacturing and financial positions support upcoming milestones.
-
Multiple antibody-based oncology programs showed strong clinical and preclinical results, with Tovecimig poised for U.S. commercialization and a projected $1B+ market. New studies and regulatory filings are planned for the coming year, supported by robust funding.
-
Key clinical milestones include strong efficacy signals for tovecimig in biliary tract cancer and promising early results for bispecific antibodies in other cancers. Regulatory strategy focuses on full approval with robust data, while commercial plans target a >$3B U.S. market opportunity.
-
Q2 2025 saw strong clinical progress, with tovecimig showing improved survival in biliary tract cancer and CTX-8371 delivering deep partial responses in early trials. Cash reserves of $101M support operations into 2027, with key data readouts and regulatory milestones expected in 2026.
-
Four antibody oncology programs are advancing, with Tevesemig showing strong efficacy in biliary tract cancer and a pivotal PFS/OS readout expected in Q4. IND filing for a novel PD1-VEGF bispecific and key data from other assets are also anticipated this year.
-
The conference highlighted a robust oncology pipeline, with Tovecimig showing significant efficacy in biliary tract cancer and multiple new trials planned. Key upcoming milestones include pivotal survival data, expansion into DLL4-positive cancers, and first-in-human studies for next-generation bispecific antibodies.
-
Four antibody-based oncology drugs are advancing, with lead candidate Tovecimig meeting its primary endpoint in a pivotal BTC trial and key PFS/OS data expected in Q4 2024. The pipeline includes differentiated bispecifics, strong market potential, and a cash runway into 2027.
-
COMPANION-002 trial data showed a significant response rate and disease control advantage in second-line biliary cancer, with regulatory submission planned and secondary endpoint data expected later this year. Expansion into other tumor types and pipeline updates are under evaluation.
-
Tevesemig plus paclitaxel demonstrated a significant improvement in overall response rate (17.1% vs. 5.3%) over paclitaxel alone in advanced biliary tract cancer, with a favorable safety profile and ongoing responses. Time-to-event analyses for PFS and OS are expected in late 2025.
-
The discussion highlighted a robust bispecific antibody platform, with CTX-009 advancing in a pivotal BTC trial and a strong commercial opportunity. Additional programs target colorectal cancer, NCAM-positive tumors, and novel PD-1/VEGF bispecifics, with key data readouts and regulatory milestones expected this year.
Fiscal Year 2024
-
Three clinical-stage antibody programs are advancing, with lead candidate CTX009 showing strong efficacy in biliary tract cancer and a pivotal trial readout expected by Q1 next year. Market opportunity exceeds $1 billion annually, and biomarker-driven studies are expanding the pipeline.
-
The company is advancing a robust oncology pipeline, with its lead DLL4 VEGF-A bispecific antibody showing unprecedented efficacy in second-line BTC. A pivotal randomized study is fully enrolled, with top-line response data expected by end of Q1 next year, and additional trials in BTC and CRC planned.
-
Three antibody-based oncology drugs are advancing, with lead asset 009 showing strong efficacy in biliary tract and colorectal cancers. Key randomized trial data are expected early next year, and new biomarker-driven and frontline studies are planned.